Texila International Journal of Public Health
ISSN: 2520-3134
DOI: 10.21522/TIJPH.2013.13.01.Art053

Dental Pulp Stem Cell-Based Therapy for Human Diseases

Abirami Devendran [1], Yamini Anandan[2], Sankarganesh Palaniyandi[3], and Ganesh Kumar Anbazhagan[2*]
[1]Department of Microbiology, Vivekanandha College of Arts and Science for Women, Tiruchengode – 637 205, Tamil Nadu, India
[2]Department of Microbiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai – 602 105, Tamil Nadu, India
[3]Department of Food Technology, Hindustan Institute of Technology and Science, Padur, Chennai - 603 103, Tamil Nadu, India

Abstract

Stem cells, which can self-renew and develop into specialized cell types, are used in stem cell therapy, an emerging multidisciplinary approach, to repair and regenerate tissue. This medication may be beneficial for a variety of conditions, such as cardiovascular disease, neurological disorders, autoimmune diseases, and certain types of cancer. However, problems like safety, scalability, and ethical quandaries persist. Dental pulp stem cells (DPSCs), derived from the soft tissue of teeth, offer a clear advantage over other stem cell sources due to their accessibility and regeneration potential. DPSCs are valuable for immunological regulation, neurological therapy, and bone regeneration since they may be obtained non-invasively from extracted teeth and differentiate into a variety of cell types, including osteoblasts, adipocytes, and neurons. DPSCs can promote tissue healing and reduce inflammation due to their immunomodulatory qualities. They also release growth factors and cytokines, which help heal damaged tissues. In clinical settings, DPSCs still have limitations despite their potential, such as the need for homogeneity and scalability. However, because of their broad differentiation potential, ease of procurement, and immune-regulatory qualities, they are positioned as a promising resource in regenerative medicine. This review highlights the characteristics, mechanisms of action, and therapeutic potential of DPSCs in the treatment of diseases, with a special focus on their role in bone regeneration, tissue repair, and neuroprotection. Further research and clinical testing are needed to get past barriers and optimize the use of DPSCs in regenerative therapies.

Keywords: *Dental Pulp Stem Cells (DPSCs), Differentiation Potential, Immunomodulation, Regenerative Medicine, Stem Cell Therapy, Tissue Repair.*

Introduction

Overview of Stem Cell Therapy

Stem Cell Therapy is a fresh and multidisciplinary approach based on using stem cells in anticipation of degeneration or wear and tear of tissues or organs. Stem cells are distinguished by their potential to differentiate into multiple specialized cell types as well as their ability to self-renew, functioning as a source for tissue repair and regeneration [1]. TE, a broad classification of stem cells used for therapeutic purposes are embryonic stem cells (ESCs) which are pluripotent, meaning they can give rise to almost any cell type found in the human body, and adult stem cells (ASCs) such as mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs), which are multipotent, limited to the differentiation of a relevant range of cells. Stem cell therapy offers

Received: 07.01.2024 Accepted: 10.02.2025 Published on: 28.03.2025
****Corresponding Author: drgkanbazhagan@gmail.com***

the potential for treating a multitude of diseases, such as neurological disorders (e.g., Parkinson's disease, spinal cord injuries), cardiovascular (e.g., heart failure), autoimmune diseases (e.g., rheumatoid arthritis) and even some cancers. These therapies can act via differentiation into the desired cell types, a paracrine effect through the release of growth factors for mediating tissue healing, or immune modulation through combating the inflammatory environment [2]. Despite this potential stem cell therapy comes with its share of challenges including but not limited to safety, ethical issues (more so with ESCs), scalability of treatments and long-term effectiveness. However, there is still a long way to go before we have a fully functional regenerative organ that is ready for full-scale use [3].

Importance of Dental Pulp as a Rich Source of Mesenchymal Stem Cells

Because of accessibility and abundance, dental pulp is a considerable source of mesenchymal stem cells (MSCs) with unique regenerative properties. Dental pulp stem cells (DPSCs) are present in the soft tissue of teeth and these cells are enriched with osteoblasts, fat, and neural cells therefore they are good for regenerative therapies [4]. DPSCs can be obtained from extracted teeth, which are considered non-surgical means, which makes their procurement much easier than procuring them from the bone marrow or adipose tissue where stem cells are also found [5]. These stem cells have an impressive growth capability and can modulate the immune system as well as regenerate tissues, these features will work well for cases of bone fractures, brain and other nerve diseases, and oral cavity dents. Unlike embryonic stem cells, society has additional issues as to the ethics of DPSC usage, deriving them from teeth that have been knocked out or shed. Also, because these cells secrete PDGF, TGF-beta, and other cytokines, they can accelerate recovery, so there is a very high possibility that they will be effective in regenerative medicine [6].

Definition and Characteristics of DPSCs

Developmental Dental Pulp Stem Cells (DPSCs) are complex and are derived from dental pulp stem cells, a soft tissue with nerves, blood vessels, and connective tissues. The stem cells have self-renewing capabilities, proliferate and can differentiate into osteoblasts (bone cells), extra fat tissues, chondrocytes (cartilage cells) and all types of neurons suited for reconstructive therapies [7]. They are highly reproducible and can be obtained from modified teeth in this case third molars or wisdom teeth which makes stem cells non-invasive and easy to work with. When combined with the fact that, DPSCs can regulate immune responses the capacity to secrete growth-creating factors such as cytokines further improves its bounds in treating inflammation and autoimmune diseases. All these qualities together make them the holy grail for applications in regenerative medicine and goodness considering the low ethical issues that they create, they are ideal for bone and tissue repair or even neurological and dental repairs [8].

Biological Properties of Dental Pulp Stem Cells

DPSCs, or Dental Pulp Stem Cells, come from the soft tissue infiltration found within the teeth. These people's teeth are specifically third molars or deciduous teeth. An enzyme such as collagenase and dispase is used to dissociate tissues and through an enzymatic digestion step; these stem cells come into being [9]. The ultimate cells are then cultured in a suitable growth medium, where they anchor themselves to the plastic surface making it possible to isolate the stem cells. In the characterization of DPSCs, the expression of several mesenchymal stem cell markers such as CD105, CD73, and CD90 is assessed by flow cytometry and the ability of the cells to differentiate into osteoblasts, adipocytes, and chondrocytes is confirmed by specific staining or gene expression analysis. In addition, their immune-modulatory function has been determined by cytokine secretion and the degree of immune suppression that they can exert [10]. Clonogenicity and proliferative capabilities are also quantified by colony-forming unit assays and cell viability tests, respectively, whereas various in vivo studies have been done which demonstrate their regenerative abilities. These methods offered an adequate description of DPSCs regarding their potential use in cell therapy for regenerative medicine [11].

Dental Pulp Stem Cells (DPSCs) are endowed with a set of characteristics that make them of interest in regenerative medicine. Self-renewal is their capability to expand by creating clones of themselves and this gives rise to an unlimited source of uncommitted cells [12]. This is an important trait for therapeutic modalities that are to be used in the long run. It's worth noting that DPSCs are most proliferative and maintain their primitive state. Multipotency is another crucial feature whereby DPSCs have the potential to transform into osteoblasts, adipocytes, chondrocytes, and neurons that enable them to repair multiple tissues including damaged or degenerated ones. Additionally, DPSCs are immunomodulatory which gives them the ability to control the immune response by down-regulating excessive inflammatory responses or facilitating the healing of tissue. They have the potential to release cytokines and growth factors altering the activation of immune cells, thus preventing autoimmune diseases and inducing repair without immune-mediated rejection [13]. These DPSC characteristics are beneficial in many regenerative therapeutic approaches. Similar to ADSCs and BMSCs, DPSCs have strong immunosuppressive qualities in terms of immunomodulation. However, they also secrete a variety of bioactive chemicals that support angiogenesis and neuroprotection, which gives them a unique ability to improve tissue repair. The drawback is that while DPSCs show promise, they still face difficulties in large-scale clinical deployment and standardization, while BMSCs have been researched more thoroughly and have a longer history of clinical uses [14].

Mechanisms of Action of DPSCs in Disease Therapy

Dental pulp stem cells (DPSCs) are extremely beneficial for regenerative medicine because of their great differentiation potential, which allows them to differentiate into a wide range of specialized cell types (Figure 1). DPSCs can develop into osteoblasts, which are in charge of bone production, given the right culture circumstances. Given that DPSCs can build mineralized matrices that resemble those made by bone cells, this potential is especially helpful for treating bone abnormalities and illnesses. Similar to this, DPSCs can differentiate into adipocytes, or fat cells, indicating their ability to produce tissues involved in energy storage and metabolic processes [15]. This ability could be helpful in the treatment of disorders such as metabolic diseases or the regeneration of tissue following trauma. DPSCs are important for cartilage repair because they can also develop into chondrocytes, which are the cells that produce cartilage. Furthermore, it has been demonstrated that DPSCs can differentiate into neurons and glial cells, which are neuronal-like cells. This suggests that DPSCs may be used to treat spinal cord injuries or neurodegenerative illnesses like Parkinson's disease. DPSCs are positioned as a flexible stem cell source for a variety of therapeutic applications in regenerative medicine because of their broad differentiation potential and propensity to release bioactive compounds that aid in tissue regeneration [16].

The term "paracrine effects" describes how Dental Pulp Stem Cells (DPSCs) can release a range of growth factors, cytokines, and other bioactive substances that affect nearby cells and tissues to encourage tissue repair and healing. Vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), hepatocyte growth factor (HGF), brain-derived neurotrophic factor (BDNF), and interleukins are only a few of the many pro-regenerative substances released by DPSCs. To repair and regenerate tissue, these released chemicals aid in promoting cell division, angiogenesis (the creation of new blood vessels), and anti-inflammatory reactions [17].

Strong immunomodulatory qualities of the cytokines generated by DPSCs aid in regulating immunological responses and reducing inflammation, which can be especially helpful in the treatment of autoimmune and inflammatory illnesses. To change the immune response from a pro-inflammatory to an anti-inflammatory state and promote tissue healing without inciting immunological rejection, DPSCs, for instance, can inhibit T-cell activity and alter macrophage polarization. Furthermore, DPSCs release substances that support the survival and development of diverse cell types, including osteoblasts for bone regeneration and neurons for neurological repair [18].

DPSCs are very useful in encouraging tissue repair, lowering scar formation, and enhancing functional recovery in a range of illnesses and traumas because of their paracrine activities, which enable them to assist and augment the surrounding tissues' inherent regenerative processes. Because of this, DPSCs are a prospective source of stem cells for both direct differentiation and their ability to promote healing through released chemicals. Dental pulp stem cells (DPSCs) are especially useful in the treatment of inflammatory and autoimmune diseases because of their strong immunomodulatory capabilities, which enable them to affect and control inflammation and immunological responses. By releasing a range of cytokines and growth factors that, depending on the tissue environment, either repress or stimulate particular immune responses, DPSCs can alter immune cell activity [19].

Their capacity to inhibit T-cell proliferation, which lowers the activation of immune cells implicated in autoimmune reactions or chronic inflammation, is one of the main immunosuppressive processes. Additionally, DPSCs can control the polarization of macrophages, causing them to change from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, which is essential for tissue healing and inflammation reduction [20]. Furthermore, DPSCs can prevent excessive immunological activation and preserve immune tolerance by blocking the activation of dendritic cells, which are essential for triggering immune responses. The anti-inflammatory environment is further improved by the release of interleukins like IL-10 and TGF-β, which encourage tissue repair and lower the chance of tissue damage from chronic inflammation. Because DPSCs can promote healing and avoid immunological rejection in transplants or during the treatment of diseases like rheumatoid arthritis, systemic lupus erythematosus, and other autoimmune disorders, their immunomodulatory capabilities are particularly significant in the field of regenerative medicine. All things considered, DPSCs' capacity to affect immune responses helps to both lower inflammation and foster an environment that is conducive to tissue regeneration and repair [21].

DPSCs in Regenerative Medicine

Tissue Regeneration

In clinical medicine, bone regeneration in critical-sized bone defects—large bone lesions that do not mend on their own—presents a major difficulty. Because of their capacity to differentiate into osteoblasts, or cells that make new bone, and to aid in bone repair, dental pulp stem cells, or DPSCs, have become a viable option for dealing with this problem. By dividing into osteogenic cells and generating bone matrix, DPSCs can regenerate bone when implanted into bone defects, aiding in the process of bone healing. Furthermore, DPSCs release important growth factors like as bone morphogenetic proteins (BMPs) and vascular endothelial growth factor (VEGF), which promote angiogenesis, or the creation of new blood vessels, which is necessary for the survival and nutrition of newly formed bone tissue. By giving DPSCs a framework that promotes cell attachment, development, and differentiation, scaffolds like collagen or hydroxyapatite are used in conjunction with them to further increase their capacity for regeneration [22]. Additionally, DPSCs have paracrine actions, releasing proteins and cytokines that assist tissue regeneration, lower inflammation, and increase cell survival. According to research conducted on animal models, DPSCs, particularly when paired with biomaterials, greatly enhance bone healing in critical-sized defects. This suggests that DPSCs could be used as a therapeutic option for patients with large bone defects, providing a viable substitute for conventional bone grafting techniques [23].



Figure 1. DPSC Differentiation into Various Types of Cells

Due to their capacity to differentiate into tenocytes (tendon cells) and chondrocytes (cartilage-forming cells), dental pulp stem cells (DPSCs) have demonstrated significant promise in the repair of cartilage and tendons, making them a viable option for the regeneration of musculoskeletal tissues. Repairing damaged or deteriorated cartilage and tendon tissues depends on DPSCs' ability to differentiate into cartilage and tendon-like cells when cultivated under particular conditions. Like other mesenchymal stem cells, DPSCs secrete important growth factors like vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-β), which support tissue healing, angiogenesis, and chondrocyte and tenocyte differentiation and survival. DPSCs can aid in the formation of cartilage-like tissue during cartilage regeneration, which can then integrate into the defect site and aid in the restoration of joint function [24]. By regenerating tendon-like tissue that closely resembles the structural characteristics of natural tendons, DPSCs can improve the mechanical strength and flexibility of damaged tendons. DPSCs have proven to be effective in repairing tendon injuries and articular cartilage abnormalities in animal models, exhibiting notable enhancements in tissue structure, function, and biomechanical characteristics. Furthermore, by lowering inflammation and promoting tissue regeneration, the paracrine actions of DPSCs—such as the release of anti-inflammatory cytokines—create the ideal healing environment. As a result, DPSCs have a lot of potential as a regenerative therapy for tendon and cartilage repair, providing a possible substitute for more conventional procedures such as tendon transplants, surgery, or cartilage implants [25].

Because dental pulp stem cells (DPSCs) can stimulate tissue repair and regeneration through both differentiation and paracrine actions, they have shown great promise in skin wound healing and epithelial regeneration. In skin wounds, DPSCs can develop into keratinocytes, the main cell type of the epidermis, which aids in the regeneration of the epithelial layer. Furthermore, DPSCs release several growth factors, including transforming growth factor-beta (TGF-β), fibroblast growth factor (FGF), and epidermal growth factor (EGF), which support collagen synthesis and fibroblast activity, thereby promoting dermal tissue healing in addition to stimulating keratinocyte migration and proliferation [26]. These elements aid in promoting wound closure, lowering the production of scars, and fostering an environment that is conducive to epithelialization—the process by which the skin regenerates its outer layer. Additionally, DPSCs have immunomodulatory qualities; they release cytokines that help control excessive inflammation, which is important for limiting the formation of scar tissue and speeding up the healing process. With increased reepithelialization, collagen deposition, and tissue regeneration, DPSCs have demonstrated a remarkable ability to speed wound healing in animal models of burn injuries and full-thickness skin wounds. Their capacity to release angiogenic factors also promotes the development of new blood vessels, which is necessary to supply oxygen and nutrients to the tissue that is mending. All things considered, DPSCs show promise as a treatment for skin wound healing and epithelial regeneration, providing a possible substitute for more traditional methods like grafts or artificial skin replacements [27].

Neurological Disorders

(DPSCs) have become a prospective treatment option for neurodegenerative diseases like Alzheimer's disease (AD), Parkinson's disease (PD), and spinal cord injury (SCI), because of their capacity to differentiate into brain cells and release neuroprotective factors. The ability of DPSCs to develop into neurons, astrocytes, and oligodendrocytes—all crucial for the regeneration and repair of damaged brain tissue—occurs in Alzheimer's disease. To slow the progression of neurodegeneration in AD, DPSCs' paracrine effects—which include the secretion of vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), and nerve growth factor (NGF)—help preserve existing neurons, encourage neuronal survival, stimulate neurogenesis, and improve synaptic plasticity. DPSCs can also assist in lowering neuroinflammation and enhance neuronal function by secreting neurotrophic substances, providing neuroprotective effects that could aid in the management of Parkinson's disease symptoms [28]. By developing into neural progenitor cells, oligodendrocytes, and astrocytes, DPSCs can aid in axonal regeneration and myelination in cases of spinal cord injury. Additionally, they release anti-inflammatory cytokines that lower inflammation-induced secondary damage and improve the conditions for spinal cord regeneration. DPSCs have demonstrated great potential in enhancing tissue healing, decreasing the formation of scar tissue, and boosting functional recovery following SCI, AD, and PD in animal models. Because of their accessibility and regeneration qualities, DPSCs are a very appealing option for treating these difficult neurodegenerative illnesses and traumas [29].

Dental pulp stem cells (DPSCs) have a variety of neuroprotective, neuronal differentiation, and functional recovery mechanisms in neurodegenerative disorders and traumas. These mechanisms include immunological regulation, paracrine signalling, and direct differentiation.

Neuroprotection

By secreting several neurotrophic factors, including vascular endothelial growth factor (VEGF), nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF), DPSCs demonstrate notable neuroprotective benefits. These elements lessen neuronal apoptosis (cell death), encourage neurogenesis (the production of new neurons), and shield already existing neurons from harm. Additionally, DPSCs emit anti-inflammatory cytokines, including interleukin-10 (IL-10), which reduce neuroinflammation, a major contributing factor to the development of neurodegenerative illnesses like Parkinson's and Alzheimer's [30].

The capacity of DPSCs to develop into neural cells—neurons, astrocytes, and oligodendrocytes—is crucial for the restoration of damaged brain tissue in neurological disorders (Figure 2). Studies conducted both in vitro and in vivo have demonstrated that DPSCs can differentiate into cholinergic neurons, which are necessary for Alzheimer's disease, or dopaminergic neurons, which are essential for the treatment of Parkinson's disease. By developing into oligodendrocytes, they can also aid in the production of myelin in spinal cord lesions, restoring the insulation of nerve fibres and enhancing neuronal transmission [31].

Functional Recovery

By combining tissue repair and cell replacement, DPSCs support functional recovery. In addition to replacing lost neurons, DPSCs promote axon regeneration, improve synaptic plasticity, and aid in the restoration of damaged neural circuits when transplanted into areas of injury or degeneration (such as the brain or spinal cord). To provide nutrients and oxygen to the regenerated tissue, they also produce substances that support the survival of transplanted cells and stimulate angiogenesis, the growth of new blood vessels. Furthermore, DPSCs' capacity to regulate the immune system lessens inflammation-induced secondary damage, creating an atmosphere that is more conducive to tissue regeneration and repair [32].



Figure 2. DPSC Utilised to Address Many Neurodegenerative Conditions

These combined mechanisms make DPSCs a promising therapeutic tool for conditions like Alzheimer's disease, Parkinson's disease, and spinal cord injuries because they enable them to provide comprehensive neuroprotective effects, stimulate the differentiation of new neurons, and promote functional recovery following neurodegenerative diseases and injuries.

Cardiovascular Diseases

Due to their capacity to differentiate into cardiac and vascular cell types, as well as their paracrine effects that support tissue repair and regeneration, dental pulp stem cells (DPSCs) have demonstrated great promise in the treatment of myocardial infarction (MI), heart failure, and vascular regeneration. Heart Infarction (MI): By developing into vascular endothelial cells and cardiomyocytes (heart muscle cells), DPSCs may help heal damaged heart tissue following a myocardial infarction. Additionally, they release growth factors like fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), which promote angiogenesis, or the creation of new blood vessels, and guarantee enough blood supply to the wounded area [33].

Heart Failure

By promoting cardiac tissue regeneration and enhancing the heart's contractility, DPSCs can aid in the restoration of heart function in the setting of heart failure. They can help restore myocardial tissue lost as a result of prior ischemia episodes by differentiating into cardiac muscle cells and forming cardiac tissue in injured areas. Additionally, DPSCs can aid in the restoration of tissue architecture, the repair of the extracellular matrix, and the development of new blood vessels, all of which increase tissue perfusion and the heart's oxygen supply—two critical functions for heart failure patients [34].

Vascular Regeneration

DPSCs can differentiate into smooth muscle and vascular endothelial cells, both of which are necessary for the development and repair of blood vessels, they play a vital role in vascular regeneration. DPSCs improve blood circulation and the delivery of nutrients to injured areas by encouraging the development of new blood vessels in ischemic tissues through the secretion of angiogenic substances such as VEGF. In diseases like atherosclerosis, vascular damage, and chronic ischemia, where tissue recovery requires the restoration of normal blood flow, this ability is especially helpful [35].

Autoimmune Diseases

Dental pulp stem cells (DPSCs) have great promise for the treatment of immune-mediated conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA) because of their capacity to stimulate tissue regeneration and immunomodulatory qualities. Through their paracrine activities, DPSCs can stimulate tissue regeneration and affect immunological responses, providing therapeutic benefits in certain chronic inflammatory disorders [36].

Rheumatoid Arthritis (RA)

By modifying the immune system to lessen inflammation, DPSCs can be extremely important in rheumatoid arthritis, a disease marked by persistent inflammation and joint deterioration. Interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), two anti-inflammatory cytokines secreted by DPSCs, inhibit the activation of pro-inflammatory immune cells such as macrophages and T-cells. This lessens the inflammatory reaction that damages joints. Additionally, DPSCs can develop into osteoblasts, which make bones, and chondrocytes, which form cartilage, which may help restore damaged bone and cartilage in afflicted joints. Furthermore, their angiogenic potential—which encourages the development of new blood vessels—may support tissue regeneration and enhance the flow of nutrients to the injured area, speeding up the healing process [37].

Multiple Sclerosis (MS)

The central nervous system (CNS) degenerates in multiple sclerosis, an autoimmune illness, mostly as a result of immune cells destroying myelin. Because DPSCs can differentiate into oligodendrocytes, which are the cells that produce myelin, they have intriguing therapeutic promise for multiple sclerosis. By restoring the protective layer surrounding nerve fibres and enhancing nerve conduction, DPSCs can encourage remyelination when transplanted into the central nervous system. Additionally, DPSCs' immunomodulatory qualities aid in lowering the autoimmune response in MS, which may slow the demyelination process and shield already damaged neurons from additional harm. Brain-derived neurotrophic factor (BDNF), one of the paracrine substances released by DPSCs, can also promote neural repair and neuronal survival [38].

Clinical Applications and Translational Challenges

Although a large portion of the research is still in the preclinical stage, preclinical and clinical studies examining the use of Dental Pulp Stem Cells (DPSCs) for diverse therapeutic purposes have produced encouraging findings. This research demonstrates how DPSCs can be used to treat a variety of illnesses, such as autoimmune disorders, cardiovascular issues, neurodegenerative diseases, and bone abnormalities.

Preclinical Research

Preclinical research, mostly carried out in animal models, has shown that DPSCs can differentiate into several cell types, including neurons, osteoblasts, chondrocytes, and cardiomyocytes, depending on the tissue type they are intended to target. In models of spinal cord injury and Alzheimer's disease, these studies have demonstrated the ability of DPSCs to stimulate neuronal regeneration and heal bone deformities and cartilage degradation. DPSCs have been demonstrated to increase vascular regeneration in ischemic tissues and cardiac repair following myocardial infarction in cardiovascular models. Preclinical research on multiple sclerosis and rheumatoid arthritis has shown that DPSCs have immunomodulatory qualities that aid in tissue healing and inflammation reduction [39].

Clinical Studies

There have been an increasing number of experiments examining the safety and effectiveness of DPSCs, even though clinical studies incorporating them are relatively scarce. The application of DPSCs for bone regeneration and wound healing has been the subject of early-phase clinical trials, with encouraging outcomes in terms of tissue repair and functional recovery. With promising indications that DPSCs can support neuronal survival and regeneration, clinical trials have also investigated the use of DPSCs in Parkinson's and Alzheimer's diseases. Clinical investigations have started to assess DPSCs' ability to improve myocardial function and vascular healing after cardiac injury in cardiovascular disease. Furthermore, studies are looking at the potential of DPSCs to influence immune responses and encourage tissue regeneration in autoimmune diseases like rheumatoid arthritis [40].

The research and use of stem cell-based therapies, such as those utilizing dental pulp stem cells (DPSCs), are significantly hampered by ethical issues and regulatory barriers. Safety, ethical sourcing, and the legal framework necessary for clinical use are the main issues here.

Ethical Concerns

Informed Consent and Patient Autonomy

Ensuring that patients are fully aware of the possible hazards and advantages associated with stem cell-based therapies is one of the main ethical problems. To prevent coercion and guarantee that patients make their own decisions, it is crucial to have clear, open, and informed consent procedures, particularly when it comes to experimental treatments. Source of Stem Cells: While dental pulp is a non-invasive and morally acceptable source for DPSCs, other stem cell types, like those from embryos or fetal tissue, may still raise questions. Because of ethical concerns about the destruction of embryos, the use of embryonic stem cells has been a particularly contentious topic [41].

Germline Editing and Genetic Manipulation

Concerns have been raised over the likelihood that genetically altering stem cells could result in heritable changes, particularly in reproductive cells. This raises ethical concerns regarding the potential for unforeseen consequences in subsequent generations. Although this is more of a problem with gene-editing technologies such as CRISPR, genetically manipulated stem cell therapies can raise similar issues [42].

Regulatory Hurdles

Safety and Effectiveness

Before approving stem cell therapies for clinical use, regulatory bodies like the FDA in the United States and the EMA in Europe demand thorough preclinical and clinical data. This involves proving that DPSCs don't develop into tumours, trigger immunological rejection, or have any other negative effects, which calls for close, ongoing patient monitoring [43].

Protocol Standardization

There are no established protocols for the administration, culture, and isolation of DPSC. For treatments to be effective, stem cell products must consistently be of high quality. Regulatory agencies need strict guidelines on quality control, cell characterization, and manufacturing processes to ensure the dependability and safety of stem cell products [44].

Allogeneic vs Autologous Therapies

Compared to allogeneic therapies, which use stem cells derived from other people, autologous stem cell therapies—in which the patient's stem cells are harvested—face fewer regulatory obstacles. Although immunological rejection is typically less of a problem with autologous therapy, regulatory permission is still necessary to guarantee that the cells are processed safely [45].

Cost and Access

Large-scale stem cell therapy approval is likewise fraught with regulatory obstacles. The availability of these medicines may be restricted by the high development expenses as well as the intricate and time-consuming regulatory procedures. Access to these treatments for patients may also be impacted by the expense of cell culture, differentiation procedures, and safe storage, particularly in environments with limited resources or lower incomes [46].

Future Perspectives

Dental pulp stem cells, or DPSCs, have a bright future in regenerative medicine, with several intriguing prospects. The range of illnesses and injuries that DPSCs may be used to treat is growing as research progresses, raising the prospect of more potent and widely available treatments (Figure 3).

Enhanced Clinical Applications

Developing treatments for a wider range of illnesses, such as cardiovascular diseases like myocardial infarction and heart failure, autoimmune diseases like rheumatoid arthritis and multiple sclerosis, and neurodegenerative diseases like Alzheimer's and Parkinson's, is one of the main future directions for DPSCs. To guarantee that DPSCs can effectively differentiate into the particular cell types needed for each disease, such as neurons, cardiomyocytes, or vascular endothelial cells, future research will concentrate on enhancing differentiation techniques. Furthermore, it is anticipated that combination treatments involving DPSCs and additional regenerative techniques (such as gene editing and scaffold-based systems) will increase their therapeutic potential [48].



Figure 3. DPSC Derived Extracellular Vesicles for Therapeutics

Improved Regeneration and Functional Recovery

Developments in 3D bioprinting, scaffold technologies, and gene editing should greatly enhance the functional recovery of tissues following damage or degeneration as DPSCs are further investigated in the context of tissue repair. For instance, improved biomaterials that promote cell survival and differentiation could make the use of DPSCs to restore complex tissues like cartilage, heart tissue, and spinal cord more effective. By incorporating DPSCs into personalized medicine, autologous therapies—which use the patient's stem cells to prevent immunological rejection—will also be possible, increasing therapy success and safety [49].

Immunomodulation and Disease Modification

DPSCs' immunomodulatory qualities have created promising opportunities for their application in the management of autoimmune disorders and inflammatory diseases. Future studies might concentrate on better utilizing these characteristics, which would enable DPSCs to control the immune response in diseases such as inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis. A deeper comprehension of the molecular processes via which DPSCs affect immune cells will make it possible to develop treatments that alter the underlying disease process in addition to regenerating tissues [50].

Clinical Translation and Regulatory Advancements

Continuous improvements in clinical trials and regulatory frameworks will move DPSCs closer to general clinical usage, even though many of their prospective uses are still in the preclinical stage. The safety and reproducibility of these treatments will be guaranteed by the standardization of procedures for DPSC isolation, expansion, and differentiation. Furthermore, laws governing regenerative medicine will probably change to address the particular difficulties presented by stem cell-based treatments, which will facilitate the use of DPSCs in clinical settings to treat a range of illnesses [51].

Ethical and Access Issues

Addressing ethical issues and expanding access to treatments will be crucial as DPSCs advance toward practical uses. Making DPSC-based treatments accessible to a larger patient population will require efforts to standardize stem cell procurement, guarantee fair access, and lower prices. While maintaining patient safety and ethical standards, increased public knowledge, education, and policymaking will help guarantee that the advantages of stem cell therapies are shared equitably [52-55].

Conclusion

To sum up, Dental Pulp Stem Cells (DPSCs) are a very promising source of mesenchymal stem cells that have a lot of therapeutic promise for a variety of illnesses. They are useful tools for tissue regeneration and repair because of their capacity to develop into a variety of cell types, such as osteoblasts, adipocytes, neurons, and cardiomyocytes. Preclinical research has shown that DPSCs are remarkably effective in treating autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, cardiovascular diseases, neurological disorders, bone abnormalities, and cartilage injuries. They are perfect for inflammatory and degenerative disorders because of their immunomodulatory qualities, which further increase their therapeutic effectiveness by lowering inflammation and modifying the immune response.

Furthermore, because dental pulp tissue is a plentiful and non-controversial source, DPSCs provide a less invasive and morally acceptable substitute for other stem cell sources. It is anticipated that developments in 3D bioprinting, scaffold technologies, and differentiation techniques may enhance the regenerative potential of DPSCs as research continues, facilitating more effective tissue repair and functional recovery.

Even though a large portion of the research is still in the preclinical and early clinical phases, further investigation into the potential of DPSCs, in conjunction with initiatives to address ethical issues, legal restrictions, and clinical difficulties, holds enormous promise for transforming the way that many diseases are treated and enhancing patient outcomes in the field of regenerative medicine.

References

[1]. Trapana, J., Weinerman, J., Lee, D., Sedani, A., Constantinescu, D., Best, T., M. Hare, J. M., 2024, Cell-based therapy in the treatment of musculoskeletal diseases. *Stem cells translational medicine,* 13(10), 959-978.

[2]. Rahman, M. M., Islam, M. R., Islam, M. T., Harun-Or-Rashid, M., Islam, M., Abdullah, S., and Mostafa-Hedeab, G., 2022, Stem cell transplantation therapy and neurological disorders: current status and future perspectives. *Biology,* 11(1), 147.

[3]. Senthil, R., Anitha, R., and Lakshmi, T., 2024, Mineralized collagen fiber-based dental Implant: novel perspectives. *Journal of Advanced Oral Research,* 15(1), 62-69.

[4]. Roato, I., Chinigò, G., Genova, T., Munaron, L., and Mussano, F., 2021, Oral cavity as a source of mesenchymal stem cells useful for regenerative medicine in dentistry. *Biomedicines,* 9(9), 1085.

[5]. Mehta, V., Negi, S., Mathur, A., Tripathy, S., Oberoi, S., Shamim, M. A., and Karobari, I., 2024, Oral health status among the transgender population of India: A systematic review and meta-analysis. *Special Care in Dentistry.*

[6]. Baraniak, P. R., and McDevitt, T. C., 2010, Stem cell paracrine actions and tissue regeneration. *Regenerative medicine,* 5(1), 121-143.

[7]. Tsutsui, T. W., 2020, Dental pulp stem cells: advances to applications. Stem cells and cloning: advances and applications, 33-42.

[8]. Ogata, K., Moriyama, M., Matsumura-Kawashima, M., Kawado, T., Yano, A., and Nakamura, S., 2022, The therapeutic potential of secreted factors from dental pulp stem cells for various diseases. *Biomedicines,* 10(5), 1049.

[9]. Al Madhoun, A., Sindhu, S., Haddad, D., Atari, M., Ahmad, R. and Al-Mulla, F., 2021, Dental pulp stem cells derived from adult human third molar tooth: a brief review. *Frontiers in Cell and Developmental Biology,* 9, 717624.

[10]. Baghaei, K., Hashemi, S. M., Tokhanbigli, S., Rad, A. A., Assadzadeh-Aghdaei, H., Sharifian, A., and Zali, M. R., 2017, Isolation, differentiation, and characterization of mesenchymal stem cells from human bone marrow. *Gastroenterology and hepatology from bed to bench,* 10(3), 208.

[11]. Ram, R. M., and Prasad, M., 2025, An unusual surgical complication: Slipped molar lodged in vocal cords and its anesthetic management. *Journal of Oral Biology and Craniofacial Research,* 15(1), 22-24.

[12]. Mattei, V., and Delle Monache, S., 2023, Dental pulp stem cells (DPSCs) and tissue regeneration: mechanisms mediated by direct, paracrine, or autocrine effects. *Biomedicines,* 11(2), 386.

[13]. Goswami, T. K., Singh, M., Dhawan, M., Mitra, S., Emran, T. B., Rabaan, A. A., and Dhama, K., 2022, Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders–Advances and challenges. *Human vaccines and immunotherapeutics*, 18(1), 2035117.

[14]. Yamada, Y., Nakamura-Yamada, S., Kusano, K., and Baba, S., 2019, Clinical potential and current progress of dental pulp stem cells for various systemic diseases in regenerative medicine: a concise review. *International journal of molecular sciences,* 20(5), 1132.

[15]. La Noce, M., Paino, F., Spina, A., Naddeo, P., Montella, R., Desiderio, V., and Laino, L., 2014, Dental pulp stem cells: state of the art and suggestions for a true translation of research into therapy. *Journal of dentistry,* 42(7), 761-768.

[16]. Luo, L., He, Y., Wang, X., Key, B., Lee, B. H., Li, H., Ye, Q., 2018, Potential roles of dental pulp stem cells in neural regeneration and repair. *Stem cells international,* (1), 1731289.

[17]. Li, F., Wang, X., Shi, J., Wu, S., Xing, W. and He, Y., 2023, Anti-inflammatory effect of dental pulp stem cells. *Frontiers in Immunology,* 14, 1284868.

[18]. Mattei, V., and Delle Monache, S., 2023, Dental pulp stem cells (DPSCs) and tissue regeneration: mechanisms mediated by direct, paracrine, or autocrine effects. *Biomedicines,* Jan 28; 11(2):386.

[19]. Anderson, S., Prateeksha, P., and Das, H., 2022, Dental pulp-derived stem cells reduce inflammation, accelerate wound healing and mediate M2 polarization of myeloid cells. *Biomedicines,* 10(8), 1999.

[20]. Li, F., Wang, X., Shi, J., Wu, S., Xing, W., and He, Y., 2023, Anti-inflammatory effect of dental pulp stem cells. *Frontiers in Immunology,* 14, 1284868.

[21]. Xue, N., Ding, X., Huang, R., Jiang, R., Huang, H., Pan, X., and Wang, Y., 2022, Bone tissue engineering in the treatment of bone defects. *Pharmaceuticals,* 15(7), 879.

[22]. Kwack, K. H., and Lee, H. W., 2022, Clinical potential of dental pulp stem cells in pulp regeneration: current endodontic progress and future perspectives. *Frontiers in Cell and Developmental Biology,* 10, 857066.

[23]. Longoni, A., Utomo, L., van Hooijdonk, I. E., Bittermann, G. K. P., Vetter, V. C., Kruijt Spanjer, E. C., and Gawlitta, D., 2020, The chondrogenic differentiation potential of dental pulp stem cells. *European Cells and Materials,* 39, 121-135.

[24]. Mattei, V., Martellucci, S., Pulcini, F., Santilli, F., Sorice, M., and Delle Monache, S., 2021, Regenerative potential of DPSCs and revascularization: direct, paracrine or autocrine effect? *Stem cell reviews and reports,* 1-12.

[25]. Mattei, V., and Delle Monache, S., 2023, Dental pulp stem cells (DPSCs) and tissue regeneration: mechanisms mediated by direct, paracrine, or autocrine effects. *Biomedicines,* 11(2), 386.

[26]. Johnson, K. E., and Wilgus, T. A., 2014, Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. *Advances in wound care,* 3(10), 647-661.

[27]. Ueda, T., Inden, M., Ito, T., Kurita, H., Hozumi, I., 2020, Characteristics and therapeutic potential of dental pulp stem cells on neurodegenerative diseases. *Frontiers in Neuroscience,* 14, 407.

[28]. Saremi, J., Mahmoodi, N., Rasouli, M., Ranjbar, F. E., Mazaheri, E. L., Akbari, M., and Azami, M., 2022, Advanced approaches to regenerate spinal cord injury: the development of cell and tissue engineering therapy and combinational treatments. *Biomedicine and Pharmacotherapy,* 146, 112529.

[29]. Blais, M., Lévesque, P., Bellenfant, S., and Berthod, F., 2013, Nerve growth factor, brain-

derived neurotrophic factor, neurotrophin-3 and glial-derived neurotrophic factor enhance angiogenesis in a tissue-engineered in vitro model. *Tissue Engineering Part A*, 19(15-16), 1655-1664.

[30]. Xiong, W., Liu, Y., Zhou, H., Jing, S., He, Y., and Ye, Q., 2022, Alzheimer’s disease: pathophysiology and dental pulp stem cells therapeutic prospects. *Frontiers in Cell and Developmental Biology,* 10, 999024.

[31]. Kulkarni, O. P., Lichtnekert, J., Anders, H. J., and Mulay, S. R., 2016, The immune system in tissue environments regaining homeostasis after injury: is “inflammation” always inflammation? *Mediators of inflammation,* 2016(1), 2856213.

[32]. Shi, X., Mao, J., and Liu, Y., 2020, Pulp stem cells derived from human permanent and deciduous teeth: Biological characteristics and therapeutic applications. *Stem cells translational medicine,* 9(4), 445-464.

[33]. Pezhouman, A., Nguyen, N. B., Kay, M., Kanjilal, B., Noshadi, I., and Ardehali, R., 2023, Cardiac regeneration–Past advancements, current challenges, and future directions. *Journal of Molecular and Cellular Cardiology.*

[34]. Li, X. L., Fan, W., Fan, B., and Zhang, Y., 2024, Dental pulp regeneration strategies: A review of status quo and recent advances. *Bioactive Materials,* 38, 258-275.

[35]. Min, Q., Yang, L., Tian, H., Tang, L., Xiao, Z., Shen, J., and Zhou, Y., 2023, Immunomodulatory mechanism and potential application of dental pulp-derived stem cells in immune-mediated diseases. *International Journal of Molecular Sciences,* 24(9), 8068.

[36]. Isomäki, P., and Punnonen, J., 1997, Pro-and anti-inflammatory cytokines in rheumatoid arthritis. *Annals of medicine,* 29(6), 499-507.

[37]. Cavallo, S., 2020, Immune-mediated genesis of multiple sclerosis. *Journal of Translational Autoimmunity,* 3, 100039.

[38]. Potdar, P. D., and Jethmalani, Y. D., 2015, Human dental pulp stem cells: Applications in future regenerative medicine. *World journal of stem cells,* 7(5), 839.

[39]. Yang, D., Solidum, J. G. N., and Park, D., 2023, Dental pulp stem cells and current in vivo approaches to study dental pulp stem cells in pulp injury and regeneration. *Journal of Bone Metabolism,* 30(3), 231.

[40]. Nijhawan, L. P., Janodia, M. D., Muddukrishna, B. S., Bhat, K. M., Bairy, K. L., Udupa, N., and Musmade, P. B., 2013, Informed consent: Issues and challenges. *Journal of advanced pharmaceutical technology and research,* 4(3), 134-140.

[41]. Ayanoğlu, F. B., Elçin, A. E., and Elçin, Y. M., 2020, Bioethical issues in genome editing by CRISPR-Cas9 technology. *Turkish Journal of Biology,* 44(2), 110-120.

[42]. Bradlow, D. D., Palmieri, A., and Salman, S. M., 2002, Regulatory frameworks for dam safety: A comparative study. *World Bank Publications.*

[43]. Yuan, B. Z., 2015, Establishing a quality control system for stem cell-based medicinal products in China. *Tissue engineering Part A,* 21(23-24), 2783-2790.

[44]. Fodor Duric, L., Basic Jukic, N., and Vujicic, B., 2024, Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy. *Journal of clinical medicine,* 13(19), 5763.

[45]. Abolarinwa, B. A., Shaw, M. K., and Lee, C. H., 2021, Perspectives on challenges to cell therapy development in Taiwan: strengthening evidential standards and ways forward. *Frontiers in Bioengineering and Biotechnology,* 9, 789043.

[46]. Amaya-Amaya, J., Montoya-Sánchez, L., and Rojas-Villarraga, A., 2014, Cardiovascular involvement in autoimmune diseases. *BioMed research international,* 2014(1), 367359.

[47]. Mehta, P. K., Levit, R. D., Wood, M. J., Aggarwal, N., O'Donoghue, M. L., Lim, S. S., and Pepine, C. J., 2023, Chronic rheumatologic disorders and cardiovascular disease risk in women. *American Heart Journal Plus: Cardiology Research and Practice,* 27, 100267.

[48]. Do, A. V., Khorsand, B., Geary, S. M., and Salem, A. K., 2015, 3D printing of scaffolds for tissue regeneration applications. *Advanced healthcare materials,* 4(12), 1742-1762.

[49]. Min, Q., Yang, L., Tian, H., Tang, L., Xiao, Z., Shen, J., and Zhou, Y., 2023, Immunomodulatory mechanism and potential application of dental pulp-derived stem cells in immune-mediated diseases. *International Journal of Molecular Sciences*, 24(9), 8068.
[50]. Yamada, Y., Nakamura-Yamada, S., Konoki, R., and Baba, S., 2020, Promising advances in clinical trials of dental tissue-derived cell-based regenerative medicine. *Stem cell research & therapy,* 11, 1-10.
[51]. Ferro, F., Spelat, R., and Baheney, C. S., 2014, Dental pulp stem cell (DPSC) isolation, characterization, and differentiation. *Stem Cells and Tissue Repair: Methods and Protocols*, 91-115.
[52]. Dresser, R., 2010, Stem cell research as innovation: expanding the ethical and policy conversation. *Journal of Law, Medicine & Ethics,* 38(2), 332-341.
[53]. Timothy, C. N., Samyuktha, P. S., and Brundha, M. P., 2019, Dental pulp stem cells in regenerative medicine–a literature review. Research Journal of Pharmacy and Technology, 12(8), 4052-4056.
[54]. Malakondaiah, S., Pavithravedhavalli, V., Kayal, L., Ryntathiang, I., and Jothinathan, M. K. D., 2024, Stem cell therapy: A new path in tackling oral cancer. *Journal of Stomatology, Oral and Maxillofacial Surgery*, 101967.
[55]. Shekar, N. D., Kayal, L., Babu, N. A., Jothinathan, M. K. D., and Ryntathiang, I., 2024, Pioneering the use of micro-biomarkers in oral cancer detection. Oral Oncology Reports, 100412.